KLK3 and posterior cortical atrophy: Patients followed in the Swiss section of the ERSPC had a different age range at enrolment, higher baseline PSA, and different rates of PCa development during follow‐up ([Stat+] patients, Aarau arm 5.3% vs. Finnish arm 4.0% [p = 0.10, chi squared test]; [Stat−] patients, Aarau arm 6.1% vs. Finnish arm 8.0% [p = 0.0001, chi squared test]).